Breaking News
July 21, 2018 - Fourth Published Clinical Trial Confirms Long-Term Safety of Niagen Supplementation at High Doses and Shows Potential for Improvement in Liver Health
July 21, 2018 - Parents say intense gun violence in PG-13 movies appropriate for teens 15 and older
July 21, 2018 - FAU researchers find possible cause of Parkinson’s disease in the patients’ immune system
July 21, 2018 - Protective qualities of ‘good cholesterol’ reduce after menopause
July 21, 2018 - Researchers develop new way to uncover hidden breast cancer tumors
July 21, 2018 - FDA approves first drug for treatment of adult AML patients with specific genetic mutation
July 21, 2018 - Top AI companies join hands to discover novel drugs for DMD
July 21, 2018 - Ferring announces FDA approval of ZOMACTON for injection in four new pediatric indications
July 20, 2018 - Researchers design proteins that can self-assemble into complex structures
July 20, 2018 - AVITA Medical expands management team to support launch of RECELL device to treat burns
July 20, 2018 - FDA Approves Tibsovo (ivosidenib) for Relapsed or Refractory Acute Myeloid Leukemia with an IDH1 Mutation
July 20, 2018 - Developmental screening and surveillance rates remain low, new study suggests
July 20, 2018 - TGen opens tissue donation portal to advance DIPG research
July 20, 2018 - Health impact of highly processed summertime staples
July 20, 2018 - Exergaming can improve health in overweight and obese children, study shows
July 20, 2018 - Postmenopausal factors may impact heart-protective qualities of ‘good cholesterol’
July 20, 2018 - MRI and blood test combination results in improved prostate cancer diagnosis
July 20, 2018 - Update Health Professional and Consumer on Recent Recalled Products
July 20, 2018 - Researchers trace Parkinson’s damage in the heart
July 20, 2018 - Wearable device designed to measure cortisol in sweat
July 20, 2018 - Scientists demonstrate a new regulation mechanism for skeletal muscles
July 20, 2018 - Exposure to mobile phone radiation may negatively impact memory performance in adolescents
July 20, 2018 - SUSU scientists find alternative method to treat post-traumatic stress disorder syndrome
July 20, 2018 - Gestational diabetes may increase offspring’s heart disease risk
July 20, 2018 - New vaccine could protect unborn babies from Zika virus
July 20, 2018 - Researchers find high mercury and methylmercury concentrations in traditional Tibetan medicine
July 20, 2018 - Brief Safety Plan Intervention in ER Can Cut Suicidal Behavior
July 20, 2018 - Toward a better understanding of Parkinson’s disease
July 20, 2018 - Med school communications office wins four national awards | News Center
July 20, 2018 - Professional baseball players with faster hand-eye coordination may have better batting performance
July 20, 2018 - Study looks into mechanisms that control sleep and wakefulness
July 20, 2018 - Scientists identify melanoma biomarkers that could help tailor immunotherapy treatments
July 20, 2018 - Research reveals long-term efficacy of drug used to treat common cause of kidney failure
July 20, 2018 - Timing of dinner associated with breast and prostate cancer risks
July 20, 2018 - Health Tip: Performing the Heimlich Maneuver
July 20, 2018 - Nearly all adolescents have eating, activity or weight-related issues
July 20, 2018 - Sage launches new web-based tool that helps explore curated genomic analyses of Alzheimer’s
July 20, 2018 - High-performance porous polymeric material for chromatography applications
July 20, 2018 - New molecule shows great promise for future treatment of many cancers
July 20, 2018 - New research project investigates alternative treatments for eye infections
July 20, 2018 - Immune T cells are built to react as fast as possible, shows study
July 20, 2018 - ZHX2 protein could offer a new treatment strategy for kidney cancer
July 20, 2018 - EKF’s Quo-Lab POC HbA1c analyzer meets international quality targets for diabetes testing
July 20, 2018 - Health burdens of very high risk drinking are potentially large, study reveals
July 20, 2018 - Using miniature drug-filled nanocarriers to target headaches and tumors
July 20, 2018 - Researchers uncover cause for progression of prostate cancer to incurable stage
July 20, 2018 - Studies highlight issues regarding black lung, opioid overdose, police violence and more
July 20, 2018 - AbbVie submits supplemental NDA to FDA for venetoclax to treat acute myeloid leukemia
July 20, 2018 - Researchers are one step closer to developing eye drops to treat age-related macular degeneration (AMD)
July 20, 2018 - Patients maintain muscle mass five years after surgically induced weight loss
July 20, 2018 - AMSBIO introduces new, powerful CRISPR/Cas9 gene editing kits
July 20, 2018 - PureTech Health collaborates with Roche to advance oral administration of antisense oligonucleotides
July 20, 2018 - Analysis reveals disparities in cancer death rates among minority groups
July 20, 2018 - Dr Maddy Parsons receives Royal Microscopical Society Life Science Medal
July 20, 2018 - Study finds link between DNA methylation and non-alcoholic fatty liver disease
July 20, 2018 - Military personnel with head trauma and football players with suspected CTE show similar brain changes
July 20, 2018 - Vidac Pharma Announces Initiation of Phase 2b Clinical Trial of VDA-1102 Ointment in Patients with Actinic Keratosis
July 20, 2018 - KKR is buying Envision Healthcare in a nearly $10B deal
July 20, 2018 - Older people with broken bones face higher risk of death for up to 10 years
July 20, 2018 - A simple pill for meth addicts on the cards
July 20, 2018 - UA researchers to repurpose ketamine to reduce side effects in Parkinson’s patients
July 20, 2018 - Child psychiatrist available on call to help assess separated immigrant children
July 20, 2018 - High bitter-taste sensitivity linked to increased risk of cancer
July 20, 2018 - Falling temperatures may lead to rise in numbers of deaths from stroke
July 20, 2018 - Supplemental oxygen prevents rise in morning blood pressure in OSA patients
July 20, 2018 - High fruit and vegetable intake linked to reduced risk of breast cancer
July 20, 2018 - Careful patient selection may help achieve good outcomes for vaginal mesh surgery
July 20, 2018 - Researchers raise viability of cloned mice using somatic cell nuclear transfer method
July 20, 2018 - 3HP for Latent TB Infection Treatment | 2018 | Newsroom | NCHHSTP
July 20, 2018 - An orange a day keeps macular degeneration away: 15-year study
July 20, 2018 - Researchers elucidate how the brain drives trial-by-trial adaptation to compensate for errors
July 20, 2018 - Understanding triple-negative breast cancer to develop better treatments
July 20, 2018 - Study compares outpatient antibiotic prescribing with traditional medical, retail clinic settings
July 20, 2018 - Immediate Monitoring With ECG Patch Ups A-Fib Diagnosis Rate
July 20, 2018 - KHN’s ‘What the Health?’ Drug prices and unicorns
July 20, 2018 - Scientists seek to better protect the eye from glaucoma
July 20, 2018 - Football training could improve bone mineral density in prostate cancer patients
July 20, 2018 - Single genetic change in gut bacteria can lead to obesity
July 20, 2018 - Research uncovers new target for therapeutic intervention in breast cancer
July 20, 2018 - WFN to highlight clean air for brain health on World Brain Day 2018
First photoactive drug to fight Parkinson’s disease

First photoactive drug to fight Parkinson’s disease

image_pdfDownload PDFimage_print
First photoactive drug to fight Parkinson’s disease
Credit: Universidad de Barcelona

An international team has designed the first potentially therapeutic photoactive drug, MRS7145, to fight Parkinson’s disease, according to the new article in Journal of Controlled Release.

This compound, which proved effective in laboratory animals in vivo, has been carried out by a team led by Francisco Ciruela, from the Faculty of Medicine and Health Sciences of the University of Barcelona, and collaborators.

Optopharmacology: beyond the limits of conventional drugs

Parkinson’s is the second most common neurodegenerative disease after Alzheimer’s and it affects more than 1 percent of the population. This disease, which affects the central nervous system, affects more than six million people worldwide, figures that could go higher than twelve million by 2030, according to data from the World Health Organization (WHO). In this disease, the neurotransmitter that controls the motor activity, dopamine, is reduced due the progressive death of dopaminergic neurons.

The action of conventional drugs is sometimes limited due several factors –lack of spatial specificity, slow and inaccurate distribution, etc.- which can reduce its therapeutic efficiency. Also, the efficiency of the traditional treatment on Parkinson’s (levodopa) diminishes over time and it requires to increase the administration of the dose or to change the drug. The adverse effects of new drugs (uncontrolled movements in the body, motor fluctuations, etc.) are another common denominator in most patients.

Optopharmacology is an innovative discipline based on the use of light –with a certain wave length- to control the activity of drugs. Therefore, light-sensitive drugs can act with a higher spatial and time precision and without creating adverse effects in the body.

MRS7145: opening the way to treat neurodegenerative diseases

The MRS7145, the first potentially therapeutic photoactive drug to fight Parkinson’s, is a photo-sensitive derivate from SCH442416, a selective antagonist of adenosine A2A receptor. In scientific bibliography, some A2A antagonist receptors came up as potential drugs to fight Parkinson’s, since they take part in the involved mechanisms in controlling the movement.

This photoactive drug is an inactive chemical compound that gets activated with light from a visible spectrum (with a 405 nm wave length) which is not harmful for the body. A series of optical fibers –planted in the striated bodies of laboratory animals- provide the irradiation of this area in the brain, which is responsible for the control of motor activity.

Lecturer Francisco Ciruela says, “once the striated body is radiated with violet light the active drug is released and blocks the adenosine A2A receptor. The blocking of adenosine receptors has an administrating effect on the activity of dopamine (pro-dopaminergic action).”

Photo-sensitive molecules that improve patients’ quality of life

Improving the spatial and temporary precision of the drug and strengthening the commitment of the patient to the therapy are some of the benefits of optopharmacology in Parkinson’s. “A fine time-space precision will enable manipulating the neural circuits in detail and set the functioning of those with therapeutic and neuroprotective purposes,” says Ciruela.

“Nowadays, in addition, there are treatments that are based on the implementation of electrodes in the brain of patients with Parkinson’s to control the electric activity of neurons. In the same lines, optical fibers could make light getting to almost any part of the body (spatial resolution), and these organs would be radiated with light controlled by an electronic device that would regulate the intensity and length of radiation (time resolution).

Maintaining the commitment of patients to the set therapeutic guideline on the long run is a big challenge for chronic diseases. “With a slow release system from the photoactive drug, such as a coupled patch with a radiation system remotely controlled by a phone App, the doctor could control in a precise manner the release of the most efficient dose of the active drug in the place of action,” says Ciruela.

Although the clinical application of this photoactive drug in patients is still far, this pharmacological innovation could lead the way to a research on new therapeutical solutions for this chronic disease. The new article, published in Journal of Controlled Release, is therefore a step forward in the field of pharmacology to design new therapeutical strategies with photo-sensitive molecules and to set innovative clinical protocols to improve patients’ quality of life.


Explore further:
First photoactive drug for pain treatment

More information:
Jaume Taura et al. Remote control of movement disorders using a photoactive adenosine A 2A receptor antagonist, Journal of Controlled Release (2018). DOI: 10.1016/j.jconrel.2018.05.033

Journal reference:
Journal of Controlled Release

Provided by:
University of Barcelona

Tagged with:

About author

Related Articles